GRI Bio, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GRI Nasdaq 2830 www.gribio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for GRI Bio, Inc.

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit - Sep 28th, 2026 6:40 am
GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock? - Sep 14th, 2026 10:00 am
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars - Sep 8th, 2026 6:15 am
GRI Bio Featured in "Why Now" On-Demand Video Webcast - Aug 27th, 2026 7:01 am
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 - Aug 24th, 2026 7:05 am
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - Jun 18th, 2026 6:31 am
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase - May 18th, 2026 7:15 am
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline - May 14th, 2026 6:35 am
Grainger H1 Earnings Call Highlights - May 14th, 2026 5:05 am
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions - Apr 8th, 2026 6:30 am
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment - Feb 17th, 2026 7:15 am
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026 - Feb 9th, 2026 9:30 am
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Feb 5th, 2026 7:15 am
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights - Feb 4th, 2026 6:45 am
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures - Jan 26th, 2026 6:30 am
GRI Bio Announces Reverse Stock Split - Jan 21st, 2026 2:01 pm
GRI Bio Announces Pricing of $8,000,000 Million Public Offering - Dec 11th, 2025 7:15 am